On the rate and extent of drug delivery to the brain

被引:379
作者
Hammarlund-Udenaes, Margareta [1 ]
Friden, Markus [1 ,2 ]
Syvanen, Stina [1 ,3 ]
Gupta, Anubha [1 ,4 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, S-75124 Uppsala, Sweden
[2] AstraZeneca R&D, Discovery DMPK & Bioanalyt Chem, Molndal, Sweden
[3] GE Hlth Care, Uppsala Imanet, Uppsala, Sweden
[4] Eisai & Co Ltd, Eisai Clin Dev, Clin Pharmacol, London W6 8 EE, England
关键词
blood-brain barrier; brain penetration; drug delivery; permeability clearance; unbound concentration;
D O I
10.1007/s11095-007-9502-2
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodology in brain drug delivery. Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacologically active drug molecule. Drug delivery to the brain can be comprehensively described using three parameters: K-p,K-uu (concentration ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and V-u,V-brain (intra-brain distribution). The permeability of the blood-brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis. K-p,K-uu can differ between CNS-active drugs by a factor of up to 150-fold. This range is much smaller than that for log BB ratios (K-p), which can differ by up to at least 2,000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference). Methods that measure the three parameters K-p,K-uu, CLin, and V-u,V-brain can give clinically valuable estimates of brain drug delivery in early drug discovery programmes.
引用
收藏
页码:1737 / 1750
页数:14
相关论文
共 120 条
[1]
AASMUNDSTAD TA, 1995, J PHARMACOL EXP THER, V275, P435
[2]
Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology [J].
Abbott, NJ .
NEUROCHEMISTRY INTERNATIONAL, 2004, 45 (04) :545-552
[3]
POSTNATAL-DEVELOPMENT OF BULK FLOW IN CEREBROSPINAL-FLUID SYSTEM OF ALBINO-RAT - CLEARANCE OF CARBOXYL-[C-14]INULIN AFTER INTRATHECAL INFUSION [J].
BASS, NH ;
LUNDBORG, P .
BRAIN RESEARCH, 1973, 52 (MAR30) :323-332
[4]
Evaluation of the utility of brain slice methods to study brain penetration [J].
Becker, S ;
Liu, XR .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) :855-861
[5]
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities [J].
Begley, DJ .
PHARMACOLOGY & THERAPEUTICS, 2004, 104 (01) :29-45
[6]
ABC transporters and the blood-brain barrier [J].
Begley, DJ .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (12) :1295-1312
[7]
MICRODIALYSIS - THEORY AND APPLICATION [J].
BENVENISTE, H ;
HUTTEMEIER, PC .
PROGRESS IN NEUROBIOLOGY, 1990, 35 (03) :195-215
[8]
Bickel U, 1996, J PHARMACOL EXP THER, V278, P107
[9]
How to measure drug transport across the blood-brain barrier [J].
Bickel U. .
NeuroRX, 2005, 2 (1) :15-26
[10]
In vivo blood-brain barrier transport of oxycodone in the rat:: Indications for active influx and implications for pharmacokinetics/pharmacodynamics [J].
Bostrom, Emma ;
Simonsson, Ulrika S. H. ;
Hammarlund-Udenaes, Margareta .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) :1624-1631